Daiichi Sankyo’s Vanflyta (quizartinib) has been recommended by the National Institute for Health and Care Excellence (NICE) ...

Likewise, physicians are challenged to comprehensively assess a patient’s status when seeing the patient only every six to 12 ...

Researchers from the Institute of Cancer Research (ICR) have found that prostate cancer patients with high levels of a ...

Novo Nordisk and NanoVation Therapeutics have entered into a multi-year partnership worth $600m to advance genetic medicines ...

Roche’s injectable PD-L1 inhibitor Tecentriq Hybreza (atezolizumab and hyaluronidase-tqjs) has been approved by the US Food ...

Wedgewood Communications has appointed Danielle Cranwell as president and global agency head to lead the evolution of the agency’s strategic vision and future direction. Cranwell brings more than two ...

Merck & Co – known as MSD outside the US and Canada – has shared positive overall survival (OS) results from a late-stage ...

Eli Lilly has announced that the US Food and Drug Administration (FDA) has approved its targeted IL-13 inhibitor Ebglyss (lebrikizumab-lbkz) to treat moderate-to-severe atopic dermatitis (AD). The ...

Merck/Daiichi Sankyo’s ADC candidate shows promise in phase 3 lung cancer trial - PMLiVE ...

Gilead Sciences and artificial intelligence (AI)-focused Genesis Therapeutics have entered into a collaboration aimed at developing small molecule therapies across multiple targets. The partners will ...

Sanofi and Regeneron’s Dupixent (dupilumab) has been approved by the Medicines and Healthcare products Regulatory Agency (MHRA) as an add-on maintenance treatment for chronic obstructive pulmonary ...

The pharmaceutical industry is committed to the development, manufacture and provision of medicines globally, a process that inevitably impacts the climate through greenhouse gases (GHG). To mitigate ...